Research programme: chemokine antagonists - Neurocrine Biosciences
Latest Information Update: 24 Feb 2011
At a glance
- Originator Neurocrine Biosciences
- Class Small molecules
- Mechanism of Action Chemokine receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Encephalomyelitis; Rheumatoid arthritis
Most Recent Events
- 31 Dec 2005 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 31 Dec 2005 No development reported - Preclinical for Encephalomyelitis in USA (unspecified route)
- 31 Dec 2005 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)